STAAR Surgical Company (STAA)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 144 | 164,003 | 192,776 | 224,024 | 183,038 | 127,432 | 94,695 | 89,968 | 86,480 | 129,242 | 202,490 | 193,067 | 199,706 | 196,246 | 173,083 | 162,344 | 152,453 | 128,338 | 116,315 | 110,851 |
| Short-term investments | US$ in thousands | 86,335 | 71,955 | 42,424 | 21,125 | 37,688 | 60,681 | 97,312 | 113,879 | 125,159 | 82,091 | 82,091 | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 70 | 66,341 | 66,170 | 62,674 | 65,036 | 56,775 | 54,194 | 47,063 | 51,716 | 45,320 | 46,514 | 41,182 | 48,802 | 46,796 | 41,801 | 36,129 | 41,236 | 33,859 | 31,589 | 29,902 |
| Cash ratio | 1,235.41 | 3.56 | 3.55 | 3.91 | 3.39 | 3.31 | 3.54 | 4.33 | 4.09 | 4.66 | 6.12 | 4.69 | 4.09 | 4.19 | 4.14 | 4.49 | 3.70 | 3.79 | 3.68 | 3.71 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($144K
+ $86,335K)
÷ $70K
= 1,235.41
The cash ratio of STAAR Surgical Company has shown a generally positive trend over the past few years. The ratio has fluctuated within a range of 3.31 to as high as 1,235.41 as of December 31, 2024.
The ratio started at 3.71 as of March 31, 2020, and experienced some variations before reaching a peak of 6.12 on June 30, 2022. This significant increase might indicate a strong ability to cover short-term liabilities with cash and cash equivalents during that period. However, it decreased to 3.31 by September 30, 2023, possibly suggesting a temporary strain on liquidity.
The ratio improved again to 3.91 as of March 31, 2024, showing a recovery in the company's cash position. The sudden spike to 1,235.41 by December 31, 2024, seems like an anomaly, possibly due to irregular or erroneous data entry.
Overall, while there have been fluctuations, the company has generally maintained a healthy cash position relative to its current liabilities, providing a buffer for potential short-term financial obligations. It is essential for stakeholders to delve deeper into the financial statements to understand the reasons behind these fluctuations, particularly the unusual spike in the cash ratio at the end of 2024.
Peer comparison
Dec 31, 2024